What does BeyondSpring do?
BeyondSpring Inc. is a Nasdaq-listed, clinical-stage biopharmaceutical company centered on oncology. It does not currently sell an approved medicine and reported no revenue in either FY2025 or Q1 2026. Its economic value therefore depends on whether clinical evidence, regulatory execution, intellectual property, and financing can convert experimental assets into approvals, partnerships, and eventually product cash flows. The company’s official company overview describes a patient-focused strategy built around first-in-class cancer therapies.
How is the company organized around its pipeline?
The continuing business is dominated by plinabulin, a small-molecule selective immunomodulating microtubule-binding agent. BeyondSpring says the drug activates GEF-H1, promotes dendritic-cell maturation, and may support both anti-cancer activity and protection against chemotherapy-induced neutropenia. The current pipeline page emphasizes anti-cancer combinations in non-small-cell lung cancer, small-cell lung cancer, checkpoint-inhibitor resistance, and antibody-drug-conjugate regimens.
| Research identity | Current position | Why it matters |
|---|---|---|
| Lead asset | Plinabulin | Nearly all continuing-company clinical and valuation logic is concentrated in one molecule. |
| Primary late-stage focus | EGFR wild-type, non-squamous NSCLC after prior PD-1/L1 therapy | DUBLIN-4 is intended to confirm the survival signal in a mechanism-enriched population. |
| Corporate structure | Cayman Islands parent; U.S. and China operations | Cross-border development expands capability but adds regulatory, tax, currency, and governance complexity. |
| SEED Therapeutics | Reported as discontinued operations after agreed partial stake sales | SEED remains an economic interest, but its expenses and assets are separated from continuing operations. |
How does BeyondSpring make money if it has no commercial product?
Today, BeyondSpring does not have a recurring operating revenue stream. Its model is a financed research-and-development model: raise equity or other capital, spend on clinical and regulatory work, create evidence and intellectual property, and then seek value through licensing, collaboration, asset monetization, regulatory approval, or direct commercialization. The absence of sales makes clinical milestones the closest equivalent to operating KPIs.
Which potential revenue paths are realistic?
| Path | Current evidence | Economic implication |
|---|---|---|
| Commercial sales | No approved product as of Q1 2026 | Requires successful trials, regulatory approval, manufacturing readiness, reimbursement, and launch execution. |
| Licensing or co-development | Plinabulin is being tested in multiple combinations and indications | Could bring upfront cash, milestones, cost sharing, and royalties without building a full commercial organization alone. |
| Asset monetization | Partial SEED stake sale announced for approximately $35.4 million gross proceeds in January 2025 | Shows that subsidiary interests can be used as a financing source, although closing timing and retained value matter. |
| Collaboration economics | Deferred revenue was $29.0 million at March 31, 2026 | The liability reflects cash or consideration received before accounting recognition; it is not equivalent to current product sales. |
Which clinical programs matter most to BeyondSpring’s future?
The central question is not how many programs appear on a pipeline chart, but whether plinabulin can produce reproducible benefit in a regulatory-ready population. BeyondSpring’s 2025 year-end update and 2025 Form 10-K position the mechanism-enriched NSCLC program as the lead value driver, while investigator-initiated combinations broaden the option set.
What does the evidence show, and what remains unproven?
| Program or dataset | Reported result | Research interpretation |
|---|---|---|
| DUBLIN-3 non-squamous subgroup | 2.5-month median OS improvement; two- and three-year survival rates doubled | Supports a focused confirmatory strategy, but subgroup selection and trial replication remain decisive. |
| Grade 4 neutropenia | Reduced from more than 30% to 5% in the updated DUBLIN-3 subgroup analysis | A combined efficacy-and-tolerability proposition could differentiate the regimen if confirmed prospectively. |
| Study 303 | 85% disease-control rate; 18.2% response rate; 66% 24-month overall survival | Encouraging Phase 2 evidence, but the small, single-country study is not a substitute for a controlled registration trial. |
| Radiation plus PD-1 study | 54% disease-control rate and 23% response rate across eight resistant tumor types | Suggests immune-priming potential while remaining early and heterogeneous. |
| ADC combinations | AACR 2026 preclinical data showed improved complete responses, survival, and tolerability | Strategically interesting, but preclinical results may not predict human clinical benefit. |
The company’s 2025 year-end update provides the detailed subgroup and combination figures. For researchers, the critical distinction is between signal generation and regulatory proof: the former creates optionality; the latter creates a commercial asset.
What does BeyondSpring’s latest quarter show?
The quarter ended March 31, 2026 shows a lean continuing operation with no revenue, modest operating expenses, and a liquidity position that declined after year-end. The freshest primary sources are the Q1 2026 Form 10-Q and the related earnings release.
How did expenses and cash flow change?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| R&D expense | $1.1M | $0.9M | Up 23%, mainly from drug manufacturing preparation for potential study initiation. |
| G&A expense | $1.2M | $1.7M | Down 33% as personnel, stock compensation, and legal advisory costs declined. |
| Continuing net loss | $2.4M | $2.6M | Slight improvement because lower G&A more than offset higher R&D. |
| Discontinued-operations result | $4.3M loss | $3.8M income | The prior-year period included a $7.0M gain on sale of subsidiary interests. |
| Operating cash used | $3.3M | $4.2M | Cash use improved partly through extended vendor payment terms. |
| Basic and diluted EPS attributable to BeyondSpring | -$0.05 | $0.11 | The swing reflects discontinued-operations accounting more than a major change in continuing expense scale. |
How financially strong is BeyondSpring?
BeyondSpring’s balance sheet is fragile in the conventional sense: it has no product revenue, recurring losses, a large accumulated deficit, and negative shareholders’ equity. Yet the company states that its March 2026 resources should cover operating expenses and capital expenditures for at least twelve months from the filing date. That statement supports near-term continuity, not full funding through a late-stage oncology program.
What did FY2025 reveal about cost structure?
| Metric | FY2025 | FY2024 | Signal |
|---|---|---|---|
| Revenue | $0 | $0 | The company remained fully pre-commercial. |
| R&D expense | $4.4M | $2.6M | Up 66% as manufacturing, clinical data work, combinations, regulatory services, and personnel increased. |
| G&A expense | $4.6M | $6.1M | Down 25% after headcount and corporate-overhead reductions. |
| Continuing net loss | $8.7M | $8.9M | Broadly stable despite the shift from administration toward development. |
| Consolidated net loss | $14.2M | $16.7M | Improved partly because of a $7.0M gain on the SEED interest sale. |
| Operating cash used | $19.8M | $16.4M | Cash burn increased because discontinued operations funded additional R&D. |
Which balance-sheet items deserve attention?
Which turning points shaped BeyondSpring’s current strategy?
BeyondSpring’s history is best understood as repeated narrowing and refocusing around plinabulin. The company began as a broad cross-border biotechnology platform, reached public markets, encountered a major regulatory setback in neutropenia prevention, streamlined operations, and then redirected the lead asset toward mechanism-selected oncology populations and combinations.
-
2010Wanchun Biotech was formed. The operating focus became capital formation, intellectual-property protection, and plinabulin development.
-
2014–15BeyondSpring Inc. was incorporated in the Cayman Islands and completed an internal restructuring, establishing the current cross-border holding-company framework.
-
2017The company completed its Nasdaq initial public offering on March 14, creating public-market access for a development-stage pipeline.
-
2021DUBLIN-3 produced a survival signal in NSCLC, but the FDA issued a Complete Response Letter for the separate CIN-prevention NDA and requested a second well-controlled trial.
-
2022Management streamlined the organization to extend cash runway after the regulatory setback, reducing the cost base and sharpening asset prioritization.
-
2025BeyondSpring agreed to sell part of its SEED interest for approximately $35.4 million and highlighted an HR of 0.72 in a mechanism-targeted DUBLIN-3 subgroup, setting up DUBLIN-4.
-
2026Plinabulin ADC-combination data expanded the scientific thesis, while SEED’s ST-01156 entered Phase 1 development and remained classified as discontinued operations.
Why was the 2021 FDA decision strategically decisive?
The Complete Response Letter stated that the single registrational PROTECTIVE-2 trial was not sufficiently robust and that a second well-controlled study would be required. That event altered financing conditions, delayed the nearest commercialization route, and made resource concentration unavoidable. The current investment case is consequently less about near-term CIN revenue and more about whether oncology survival evidence can support a new, narrower path.
What gives BeyondSpring a competitive position?
BeyondSpring does not possess the scale moat of a large pharmaceutical company. Its potential advantage is asset-specific: a differentiated mechanism, an accumulated clinical safety database, long-dated patent claims, and evidence that plinabulin may improve both efficacy and tolerability when combined with established cancer therapies. The 2025 Form 10-K reported 19 issued U.S. patents and patent coverage in 34 foreign jurisdictions, with relevant expirations scheduled between 2033 and 2042 before potential extensions.
Where is the company concentrating its research budget?
Who competes with the plinabulin strategy?
| Competitive pressure | Examples of alternatives | BeyondSpring’s proposed differentiation |
|---|---|---|
| Post-checkpoint NSCLC treatment | Docetaxel-based regimens, targeted combinations, and other immuno-oncology approaches | Potential survival benefit in a biomarker- and mechanism-enriched population. |
| ADC combination strategies | Dose modification, supportive care, and competing agents intended to improve durability or tolerability | Preclinical evidence of better complete responses, survival, and mitigation of dose-limiting toxicity. |
| CIN prevention | G-CSF products and established supportive-care protocols | Early-onset mechanism and reduced severe neutropenia, but the FDA requires additional confirmatory evidence. |
| Capital and execution | Large pharma and better-funded biotechnology companies | A focused organization can move selectively, but limited resources constrain trial scale and commercialization options. |
Who owns BeyondSpring stock, and how is it governed?
BeyondSpring has one class of ordinary shares, with one vote per share. It is not a dual-class company, but founder influence remains meaningful because co-founder, chair, and CEO Lan Huang beneficially owned 16.52% as of February 27, 2026. The ownership data are contained in the 2025 Form 10-K; the company’s 2025 proxy statement provides meeting and governance context.
Which holders and governance facts matter most?
| Holder or group | Shares beneficially owned | Stake | Why it matters |
|---|---|---|---|
| Lan Huang | 6,942,790 | 16.52% | Founder leadership, board chairmanship, and ownership align strategy around the long-term plinabulin thesis but create key-person concentration. |
| Decheng Capital affiliates | 3,800,702 | 9.24% | The only disclosed external holder above 5% in the ownership table. |
| All directors and executive officers | 7,623,313 | 18.17% | Insiders can exert substantial influence if acting together, while still lacking majority control. |
| Ordinary shares outstanding | 41,119,820 | 100.00% | Ownership percentages were calculated against this February 27, 2026 base. |
| Options exercisable within 60 days | 1,501,892 | Not a separate voting class | Potential dilution is relevant when comparing economic ownership and fully diluted valuation. |
What opportunities and risks could change BeyondSpring’s outlook?
BeyondSpring’s opportunity set is unusually convex: a successful confirmatory program or valuable partnership could transform a company with no current sales, while a failed trial, regulatory delay, or financing gap could sharply reduce strategic flexibility. The Q1 update’s AACR 2026 data announcement expands the scientific opportunity, but management’s own filings stress that preclinical results may not predict clinical outcomes.
Which upside drivers are most concrete?
What could weaken the story?
What is the key takeaway from BeyondSpring analysis?
BeyondSpring is not appropriately analyzed with conventional revenue multiples or a steady-state earnings forecast. It is a milestone-driven biotechnology company whose value is concentrated in plinabulin’s probability-adjusted future cash flows, the cost and timing of DUBLIN-4, partnership terms, remaining patent life, and the dilution needed to reach decisive data.
Which variables matter in a DCF or probability-adjusted model?
What should students, researchers, and investors monitor next?
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.